{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:31:57Z","timestamp":1792481517333,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.xjidi.2025.100397","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:36:58Z","timestamp":1751636218000},"page":"100397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Primary Malignancy Risk after Initiation of Biologic Therapy in Patients with Psoriasis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3072-6732","authenticated-orcid":false,"given":"Chunghwan","family":"Ro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4995-841X","authenticated-orcid":false,"given":"Ana","family":"Ormaza Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1242-7960","authenticated-orcid":false,"given":"Waleed","family":"Adawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5695-9227","authenticated-orcid":false,"given":"Alexander","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6783-1904","authenticated-orcid":false,"given":"Clinton W.","family":"Enos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2025.100397_bib1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.xjidi.2025.100397_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2016.10.006","article-title":"Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population","volume":"76","author":"Asgari","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2025.100397_bib3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2025.100397_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.xjidi.2025.100397_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jdv.19520","article-title":"Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study","volume":"38","author":"Kridin","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2025.100397_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","article-title":"US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"17","author":"Lebwohl","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.xjidi.2025.100397_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2025.100397_bib8","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2025.100397_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2025.100397_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1294416","article-title":"Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026725000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026725000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:07:13Z","timestamp":1769522833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026725000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2667026725000530"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2025.100397","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Primary Malignancy Risk after Initiation of Biologic Therapy in Patients with Psoriasis","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2025.100397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100397"}}